Last reviewed · How we verify
NCT05994053
Neuromodulation for a Novel OCD Biomarker and Treatment
NA trial testing high definition transcranial alternating current stimulation in OCD in 90 participants. Currently enrolling.
31 August 2026
Quick facts
| Lead sponsor | Boston University Charles River Campus |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 July 2024 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 August 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- high definition transcranial alternating current stimulation
Conditions studied
- OCD — all drugs for OCD →
Sponsor
Boston University Charles River Campus
Who can join
18 and older, any sex, with OCD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study by Dr. Reinhart and his team will test a new, non-invasive, and well-tolerated neuromodulation method for reducing OCD symptoms, based on reward-related rhythms of the orbitofrontal cortex (OFC; a brain region responsible for reward, decision making and other crucial functions that is affected by OCD). This proposal is based on highly encouraging preliminary data in both subsyndromal and treatment-resistant populations that shows rapid reductions in OCD behaviors that last at least 1-3 months. Using high-definition transcranial alternating current stimulation (HD-tACS) guided by EEG brain wave recordings, the study will test whether repetitive modulation of relevant rhythm activity in the OFC can lead to rapid (within five days) and sustainable (up to three months) OCD symptom reduction. This research aims to increase knowledge of OCD and development of effective treatment with minimal side effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05994053
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for OCD
Currently open trials in the same condition.
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT06282146 — Testing a Transdiagnostic TMS Treatment Target · EARLY_PHASE1 · active not recruiting
- NCT06978452 — Behavioural Development, Long-term Outcomes and Opportunities to Optimize Youth Mental Health Trajectories · recruiting
- NCT06731426 — Multi-session, Personalized Cognitive Bias Modification for Thought-Action-Fusion · NA · recruiting
- NCT06050369 — Objective Characterizatoion of Repetitive Behaviors · NA · recruiting
Other Boston University Charles River Campus trials
Trials by the same sponsor.
- NCT07461584 — Memory Enhancement in Aging With Optimal Dosing · EARLY_PHASE1 · not yet recruiting
- NCT07208318 — Restructuring the Alpha-Gamma Code in Aging Vision · EARLY_PHASE1 · not yet recruiting
- NCT06182241 — Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South · NA · not yet recruiting
- NCT07158801 — Project EMPOWER-OCD · Phase 1 · not yet recruiting
- NCT05624931 — Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05994053 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston University Charles River Campus
- Last refreshed: 17 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05994053.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing